This article identifies some of the hot new publications in the infectious diseases and antimicrobial stewardship literature released in December 2018. This list is derived from content circulating on Twitter.
Written By: Bassam Ghanem, Pharm.D., MS, BCPS
Edited By: Timothy P. Gauthier, Pharm.D., BCPS-AQ ID
[Last updated: 1 January 2019]
In this monthly column two pharmacists that utilize Twitter to stay current on literature (@ABsteward [B.G.] & @IDstewardship [T.G.]) identify some of the hot new articles in the fields of antimicrobial stewardship & infectious diseases.
The following are some of the new publications we found most interesting or noteworthy in December of 2018…
1. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial | CID
This RCT showed that an antibiotic course of 7 days was non-inferior to 14 days in patients with Gram-negative bacteremia achieving clinical stability before day 7.
2. Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety | OFID
https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofy331/5235615
This RCT showed that 2-doses regimen of weekly dalbavancin can be effective and well-tolerated for the treatment of osteomyelitis in adults.
3. IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs. Meropenem in the Treatment of Complicated Intra-Abdominal Infections | CID
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciy1029/5250914
This RCT showed that eravacycline was noninferior to meropenem in adult patients with cIAI, including infections caused by drug-resistant pathogens.
4. Duration of Exposure to Antipseudomonal Beta-lactam Antibiotics in the Critically Ill and Development of New Resistance | Pharmacotherapy
https://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1002/phar.2201
This retrospective study showed that each additional day of exposure to antipseudomonal beta-lactam antibiotics in critically ill patients increases the risk for the development of new antibiotic resistance.
5. Impact of de-escalation on prognosis of patients with bacteraemia due to Enterobacteriaceae: a post-hoc analysis from a multicenter prospective cohort | CID
A post-hoc analysis from a multicenter prospective cohort study showed that de-escalation in patients with monomicrobial bacteraemia due to Enterobacteriaceae was not associated with a detrimental impact on clinical outcome.
6. Impact of a Prescriber-driven Antibiotic Time-out on Antibiotic Use in Hospitalized Patients | CID
This multicenter quasi-experimental study of a provider-driven antibiotic time-out showed that single time-outs without input from antibiotic stewardship teams are insufficient to optimize antibiotic prescribing in hospitalized Patients.
ADDITIONAL NEW & NOTABLE PUBLICATIONS
Pharmacokinetics and Pharmacodynamics of Beta-lactamase Inhibitors | Pharmacotherapy
Omadacycline: A New Tetracycline Antibiotic | Annals of pharmacotherapy
Plazomicin, a Next-Generation Aminoglycoside | Pharmacotherapy
Prevention of Clostridium difficile Infection in Critically Ill Adult | Pharmacotherapy
A Cluster of Cefepime-induced Neutropenia during Outpatient Parenteral Antimicrobial Therapy | CID
Tolerability of long-term fluconazole therapy | JAC
It is time to define antimicrobial never events | ICHE
All aboard!: Involvement of medical and pharmacy trainees in antimicrobial stewardship | ICHE
RECOMMENDED TO YOU
